Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zentiva Set To Acquire Romania's Solacium

Executive Summary

Zentiva has signed its first acquisition after it was carved out from Sanofi last year to become an independent company, entering into a shared purchase agreement with Siyiara to acquire Romania-based food supplement and OTC medicines producer Solacium.

You may also be interested in...



Zentiva Invests €27m In Prague Plant

Zentiva has announced that it is investing a further €27m in expanding its flagship manufacturing plant in Prague, having already pumped €35m into the site over the past three years.

Zentiva Opens India Office As It Completes Ankleshwar Plant Deal

Zentiva is opening a dedicated Indian office in Mumbai to support the Ankleshwar manufacturing facility that it has just acquired from former parent company Sanofi.

Alvogen And Zentiva Complete CEE Deal

Alvogen’s central and eastern European business, which started up in 2010, has now been sold to the Zentiva group. Zentiva plans to combine both companies’ branded generics and OTC businesses in the CEE region.

Related Content

Topics

UsernamePublicRestriction

Register

GB140156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel